On March 14, 2023 Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, reported new dates for the publication of its 2022 full-year results and the holding of its annual general meeting (Press release, Onxeo, MAR 14, 2023, View Source [SID1234628655]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s Board of Directors decided to schedule the publication of the 2022 full-year results on April 14, 2023, after market close, and the holding of its annual general meeting on June 6, 2023. The date for the publication of the 2023 half-year results, scheduled for September 28 after market close, remains unchanged.